China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)
China · Delayed Price · Currency is CNY 16.07
-0.03 (-0.19%)
Nov 6, 2026, 3:00 PM CST
SHA:600062 Revenue
China Resources Double-Crane Pharmaceutical had revenue of 2.45B CNY in the quarter ending September 30, 2026, a decrease of -3.59%. This brings the company's total for the last twelve months to 10.71B, down -2.82% year-over-year. In the year 2025, China Resources Double-Crane Pharmaceutical had annual revenue of 11.00B, down -1.88%. That makes China Resources Double-Crane Pharmaceutical the 5,765th largest company in the world by revenue and 764th in China.
Revenue (ttm)
10.71B
Revenue Growth
-2.82%
P/S Ratio
1.56
Revenue / Employee
808.92K
Employees
13,184
Market Cap
16.60B
Revenue by Segment
- Non-Infusion 8.46B 75.4%
- Infusion 2.76B 24.6%
Fiscal year ended Dec 31, 2025 See the full SHA:600062 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.00B | -210.83M | -1.88% |
| Dec 31, 2024 | 11.21B | -98.52M | -0.87% |
| Dec 31, 2023 | 11.31B | 1.68B | 17.50% |
| Dec 31, 2022 | 9.63B | 513.80M | 5.64% |
| Dec 31, 2021 | 9.11B | 607.58M | 7.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.